Clinical Trial Update: Study of Sorafenib/Cetuximab in Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document summarizes the completion of a Phase 1/2 clinical trial evaluating sorafenib in combination with cetuximab for head and neck squamous cell carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Nexavar (Sorafenib)

Snippet

Sponsor: Duke University | Conditions: Squamous Cell Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-12-08